Urol. praxi. 2017;18(3):119-121 | DOI: 10.36290/uro.2017.027

Overview of diagnosis and treatment of urinary tract infections in patients with multiple sclerosis

MUDr. Eva Burešová, MUDr. Pavel Kratochvíl, MUDr. Aleš Vidlář, Ph.D., FEBU
Urologická klinika LF UP a FN Olomouc

Urinary tract infections (UTIs) can have a profound effect on the course and prognosis of patients with multiple sclerosis (MS). Inroutine practice, they are encountered on a daily basis by the physicians in charge of these patients. However, there is still lackingan unequivocal recommendation that urologists, neurologists, and general practitioners should follow. The present review dealswith this issue, including the diagnosis and treatment of UTIs in patients with MS.

Keywords: urinary tract infections, multiple sclerosis, neurogenic bladder, multiple sclerosis relapse

Published: August 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Burešová E, Kratochvíl P, Vidlář A. Overview of diagnosis and treatment of urinary tract infections in patients with multiple sclerosis. Urol. praxi. 2017;18(3):119-121. doi: 10.36290/uro.2017.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hartung HP, et al. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 2015; 21(1): 22-34. Go to original source... Go to PubMed...
    2. Polman CH, et al. A randomized placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899-910. Go to original source... Go to PubMed...
    3. Cross AH, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180(1-2): 63-70. Go to original source... Go to PubMed...
    4. Frohmann TC, et al. Uhthoffs phenomena in MS-clinical features and pathophysiology. Nat Rev Neurol 2013; 9: 535-540. Go to original source... Go to PubMed...
    5. Lublin FD, et al. Exacerbation recovery and the progression of multiple sclerosis. Neurology 2000; 54: A216-A217.
    6. Mackenzie IS, et al. Incidence and prevalence of multiple sclerosis in UK 1990-2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 2014; 85: 76-84. Go to original source... Go to PubMed...
    7. De Seze M, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult scler J 2007; 13(7): 915-928. Go to original source... Go to PubMed...
    8. Jick SS, Li L, et al. Epidemiology of multiple sclerosis. Results from large observartion study in UK. J Neurol 2015; 262(9): 2033-2041 Go to original source... Go to PubMed...
    9. Marrie RA, et al. Dramatically changing rates nad reasons for hospitalization in multiple sclerosis. Neurology 2014; 83(10): 929-937. Go to original source... Go to PubMed...
    10. Manack A, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in US claims database. Neurourol Urodyn 2011; 30(3): 395-401. Go to original source... Go to PubMed...
    11. Buljevac D, Flash HZ, Hop WCJ, et al. Prospective study on the relationship between infection and multiple sclerosis exacerbation. Brain 2002; 125(5): 956-960. Go to original source... Go to PubMed...
    12. Edlich RF, et al. Multiple sclerosis and asymptomatic urinary tract infection. J Emerg Med 1990; 8(1): 25-28. Go to original source... Go to PubMed...
    13. Goetz LL, el al. Strategies for preventive of urinary tract infections in neurogenic bladder dysfunction. Phys Med Rehabil Clin N Am 2014; 25(3): 605-618. Go to original source... Go to PubMed...
    14. Deville WL, Yzermans JC, van Duijn NP, et al. The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. BMC Urol 2004; 4: 4. Go to original source... Go to PubMed...
    15. Uroweb. EAU guidelines on urological infections, http://uroweb.org/guideline/urological-infections/ (2015).
    16. Fowler CJ, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80(5): 470-477. Go to original source...
    17. Vasudeva P, et al. Factors implicated in pathogenesis of urinary tract infections in neurogenic bladders: Some revered, few forgotten, others ignored Neurourol Urodyn 2014; 33(1): 95-100. Go to original source... Go to PubMed...
    18. Uroweb. EAU guidelines on neuro-urology, http://uroweb.org/guideline/neuro-urology/ (2015)
    19. Edokpolo LU, Stavris KB and Foster HE. Intermittent catheterization and recurrent urinary tract infection in spinal cord injury. Top Spinal Cord Inj Rehabil 2012; 18(2): 187-192. Go to original source... Go to PubMed...
    20. Rakusa M, et al. Testing for urinary tract colonization before high dose corticosteroid treatment in acute multiple sclerosis relapse: prospective algorithm validation. Eur J Neurol 2013; 20: 448-452. Go to original source... Go to PubMed...
    21. Walsh DA, et al. Fatal acute pyelonephritis following pulsed methyprednisone for rheumatoid arthritis.Ann Rheum Dis 1990; 49: 955-956. Go to original source... Go to PubMed...
    22. Albert X, Huertas I, Pereiro II, et al. Antibiotics for preventing recurrent urinary tract infection in nonpregnant women. Cochrane Database Syst Rev 2004; 3: CD001209. Go to original source... Go to PubMed...
    23. National Institute for Health and Care Excellence (NICE). Urinary incontinence in neurological disease: Management of lower urinary tract dysfunction in neurological disease (CG148). London: NICE, 2012.
    24. Wang CH, et al. Cranberry containing products for prevention of urinary tract infections in susceptible populations: A systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172(13): 988-996. Go to original source... Go to PubMed...
    25. Jepson R, et al. Cranberry products and prevention of urinary tract infections. JAMA 2013; 310(13): 1395-1396. Go to original source... Go to PubMed...
    26. Gallien P, et al. Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: A multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler J 2014; 20(9): 1252-1259. Go to original source... Go to PubMed...
    27. Schaeffer AJ, et al. Effect of carbohydrates on adherence of Escherichia coli to human urinary tract epithelial cells. Infect Immun 1980; 30(2): 531-537. Go to original source... Go to PubMed...
    28. Kranjčec B, Papeš D, Altarac S. d-mannose powder for prophylaxis of recurrent urinary tract infections in women: A randomized clinical trial. World J Urol 2013; 32(1): 79-84. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.